Eyenovia (EYEN) Competitors

Eyenovia (NASDAQ:EYEN) and Trinity Biotech (NASDAQ:TRIB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, community ranking, valuation and earnings.

Do analysts prefer EYEN or TRIB?

Eyenovia currently has a consensus target price of $2.00, suggesting a potential upside of 12.99%. Given Eyenovia's stronger consensus rating and higher possible upside, research analysts clearly believe Eyenovia is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyenovia	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Trinity Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is EYEN or TRIB more profitable?

Trinity Biotech has a net margin of -34.39% compared to Eyenovia's net margin of -114,639.41%. Trinity Biotech's return on equity of 0.00% beat Eyenovia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyenovia	-114,639.41%	-1,108.24%	-139.36%
Trinity Biotech	-34.39%	N/A	-21.37%

Which has better earnings & valuation, EYEN or TRIB?

Trinity Biotech has higher revenue and earnings than Eyenovia. Trinity Biotech is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyenovia	$57.34K	87.36	-$27.26M	-$58.40	-0.03
Trinity Biotech	$61.56M	0.20	-$24.02M	-$2.82	-0.25

Does the media prefer EYEN or TRIB?

In the previous week, Eyenovia had 3 more articles in the media than Trinity Biotech. MarketBeat recorded 7 mentions for Eyenovia and 4 mentions for Trinity Biotech. Eyenovia's average media sentiment score of 0.84 beat Trinity Biotech's score of -0.72 indicating that Eyenovia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyenovia	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Which has more risk and volatility, EYEN or TRIB?

Eyenovia has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Trinity Biotech has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in EYEN or TRIB?

25.8% of Eyenovia shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 7.1% of Eyenovia shares are held by insiders. Comparatively, 8.2% of Trinity Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in EYEN or TRIB?

Trinity Biotech received 161 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 69.79% of users gave Trinity Biotech an outperform vote while only 64.21% of users gave Eyenovia an outperform vote.

Company	Underperform	Outperform
Eyenovia	Outperform Votes 174 64.21%	Underperform Votes 97 35.79%
Trinity Biotech	Outperform Votes 335 69.79%	Underperform Votes 145 30.21%

Summary

Trinity Biotech beats Eyenovia on 11 of the 17 factors compared between the two stocks.